AGO TUMOR - AN OVERVIEW

Molecular typing relies on molecular genetic screening and is not nevertheless routinely obtainable. Molecular subtypes and immunohistochemical surrogate markers of the tumors (HR, HER2, triple negative) correlate in about 70%. The differentiation of luminal A and B subtypes by HR standing and proliferation markers like Ki-67 may be useful, but a p